Tags

Type your tag names separated by a space and hit enter

Tuberculosis vaccines: hopes and hurdles.
Infect Disord Drug Targets. 2013 Oct; 13(5):318-21.ID

Abstract

Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.

Authors+Show Affiliations

Ahsan MJ
No affiliation info available
Garg SK
No affiliation info available
Vashistha B
No affiliation info available
Sharma P
Maharishi Arvind College of Pharmacy, Jaipur, Rajasthan 302 023, India. jawedpharma@gmail.com.

MeSH

Antitubercular AgentsBCG VaccineDrug DesignGlobal HealthHIV InfectionsHumansMedication AdherenceMycobacterium tuberculosisTuberculosisTuberculosis VaccinesVaccines, Attenuated

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24304353

Citation

Ahsan, Mohamed J., et al. "Tuberculosis Vaccines: Hopes and Hurdles." Infectious Disorders Drug Targets, vol. 13, no. 5, 2013, pp. 318-21.
Ahsan MJ, Garg SK, Vashistha B, et al. Tuberculosis vaccines: hopes and hurdles. Infect Disord Drug Targets. 2013;13(5):318-21.
Ahsan, M. J., Garg, S. K., Vashistha, B., & Sharma, P. (2013). Tuberculosis vaccines: hopes and hurdles. Infectious Disorders Drug Targets, 13(5), 318-21.
Ahsan MJ, et al. Tuberculosis Vaccines: Hopes and Hurdles. Infect Disord Drug Targets. 2013;13(5):318-21. PubMed PMID: 24304353.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tuberculosis vaccines: hopes and hurdles. AU - Ahsan,Mohamed J, AU - Garg,Shiv K, AU - Vashistha,Bharat, AU - Sharma,Piush, PY - 2013/11/01/received PY - 2013/11/18/revised PY - 2013/11/19/accepted PY - 2013/12/6/entrez PY - 2013/12/7/pubmed PY - 2014/12/15/medline SP - 318 EP - 21 JF - Infectious disorders drug targets JO - Infect Disord Drug Targets VL - 13 IS - 5 N2 - Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India. SN - 2212-3989 UR - https://www.unboundmedicine.com/medline/citation/24304353/Tuberculosis_vaccines:_hopes_and_hurdles_ DB - PRIME DP - Unbound Medicine ER -